Pairing the actin-directed effects of ATM-3507 with the microtubule-targeting drug vincristine, in the context of the R-CHOP, is the most likely manner in which anti-tropomyosin drugs could be used to increase the efficacy of DLBCL treatment regimens. This evidence concerns the gene ATM and diffuse large B-cell lymphoma.